22 Result(s)
within
Niels Vande Casteele
-
Article
Open AccessReverse metabolomics for the discovery of chemical structures from humans
Determining the structure and phenotypic context of molecules detected in untargeted metabolomics experiments remains challenging. Here we present reverse metabolomics as a discovery strategy, whereby tandem m...
-
Article
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in the pathogenesis of inflammato...
-
Article
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel
-
Article
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease
Immune cell trafficking is a critical element of the intestinal immune response, both in homeostasis and in pathological conditions associated with inflammatory bowel disease (IBD). This process involves adhes...
-
Article
Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review
Patients treated with immune checkpoint inhibitors (ICIs) may develop ICI-associated enterocolitis, for which there is no approved treatment.
-
Article
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease
Certolizumab pegol (CZP) is effective for moderately to severely active Crohn’s disease (CD). Higher plasma concentrations are associated with better outcomes and increased drug clearance is the driver of subt...
-
Article
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Immunogenicity with formation of anti-drug antibodies (ADA) to biologics is an important reason for treatment failure in inflammatory bowel disease (IBD). Our aim was to assess the rate of ADA, the effect of c...
-
Article
Open AccessAssociation Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
The aim of this study was to assess the relationship between serum vedolizumab (VDZ) concentrations and antibodies to VDZ (ATV) in a large cohort of patients with inflammatory bowel diseases. Furthermore, we e...
-
Article
Open AccessMeta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis
Publicly available ulcerative colitis (UC) gene expression datasets from observational studies and clinical trials include inherently heterogeneous disease characteristics and methodology. We used meta-analysi...
-
Article
Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
-
Article
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
In Crohn’s disease and ulcerative colitis, inflammation is not limited to the digestive tract. Extraintestinal manifestations (EIMs), which affect up to 50% of patients, can substantially impair quality of lif...
-
Article
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Cytokines are involved in intestinal homeostasis and pathological processes associated with inflammatory bowel disease (IBD). The biological effects of cytokines, including several involved in the pathology of...
-
Article
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine
Monoclonal antibody (mAb) therapies have revolutionized the treatment of several chronic inflammatory diseases, including the inflammatory bowel diseases (IBD), Crohn’s disease, and ulcerative colitis. While e...
-
Article
Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease
Infliximab, a monoclonal antibody directed against tumor necrosis factor-α, is being evaluated as adjunctive therapy to intravenous immunoglobulin (IVIG) for treatment of young children with acute Kawasaki dis...
-
Article
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC). It has been sh...
-
Article
Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease
Certolizumab pegol is an effective biologic for patients with Crohn’s disease (CD). Individual differences in certolizumab pegol apparent clearance (CL/F) affect exposure and possibly efficacy. A previously de...
-
Article
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis
Ulcerative colitis (UC) is a relapsing-remitting chronic inflammatory disorder affecting the mucosal surface in a continuous manner from the rectum through part of, or the entire, colon. Patients with severe d...
-
Article
Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview
-
Article
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview
The introduction of biologic therapy has revolutionized the treatment of inflammatory bowel disease (IBD). However, like all therapeutic proteins, monoclonal antibodies have immunogenic potential which is infl...
-
Article
Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn’s Disease: Avoiding Failure While Lowering Costs?
